ACS BrightEdge and current portfolio companies have the potential to impact more than 3.5 million patients and their families per year.

On May 21, 2024, over 60 leaders and practitioners from across the health care impact investing landscape gathered for Advancing Impact: A BrightEdge Roundtable.

ACS BrightEdge Poised to Help Improve 1.5 Million Lives By Investing in Cancer-Focused Therapies and Technologies

Program to support and fund scientific founders and their early-stage companies among American Cancer Society-affiliated postdoctoral and early career researchers

CellCentric to present inobrodib Phase I multiple myeloma efficacy and safety data at the American Society of Haematology

Cancer startups aren’t exactly underfunded — as a disease area, oncology has commanded investors’ attention for the last decade. But the American Cancer Society sees gaps.

The biotech venture firm will bring the society’s BrightEdge venture arm into cancer startup deals

The company is currently enrolling patients in a multi-center Phase 1 clinical trial for the treatment of recurrent glioblastoma (GBM)

Lyda Hill Philanthropies and Resonance Philanthropies Join Exclusive ACS BrightEdge Founders Circle

In 2021, BrightEdge reemerged during the darkness of the COVID-19 pandemic with resolve and focus to pave new paths for the American Cancer Society (ACS), for healthcare innovation, and for people with cancer and their caregivers.

ATLANTA, May 19, 2022 -- The American Cancer Society’s impact venture capital fund, BrightEdge LLC, today reported $9.7 million in realized and unrealized investment gains on $18.5 million in invested capital through year-end 2021. BrightEdge’s net asset value now stands at roughly $77 million, including recent donations and an additional $40 million investment from the American Cancer Society (ACS).

SAN DIEGO and BOSTON, April 12, 2022 /PRNewswire/ -- Persephone Biosciences Inc., a synthetic biology company reimagining patient and infant health, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration to develop a novel therapeutics based on the bacterial genus Bacteroides

SAB to provide meaningful guidance as company begins first-in-human (FIH) clinical trial of their proprietary, non-invasive sonodynamic drug-device therapy system for recurrent high-grade gliomas

Alice Pomponio thinks it's sensible for an organization like the American Cancer Society to be involved in venture capital. “We have the knowledge, the insights, the data, to do things that others can't,” says Pomponio, the managing director of BrightEdge, a donor-funded, philanthropic impact fund.

New investors include US life science investors HealthQuest Capital, Casdin Capital, and American Cancer Society BrightEdge, and Asia-based global healthcare investors Tybourne Capital Management and NSG Ventures Following the most recent strategic investment of $26 million from Guardant Health, the company has now secured more than $135 million in total ahead of its planned KOSDAQ IPO next year

Digital financial health company is joined by strategic investors Citi, OSF Ventures, and American Cancer Society’s impact investment fund, BrightEdge.

Immunitas' Series B financing was led by Agent Capital. Funding will be used to advance their novel NK and T cell modulator IMT-009 for the treatment of solid tumor and hematological cancers with an anticipated IND filing in 1H 2022.

Oversubscribed round co-led by Cormorant Asset Management and Fairmount Funds, supported by a strong syndicate of new and existing investors

BrightEdge participates in Auron Therapeutics seed round.

BrightEdge Announces Second Investment in Freenome, Technology Firm Focused on Early Detection for Cancer

Checkmate Pharmaceuticals (NASDAQ: CMPI), a clinical stage biotechnology company focused on developing proprietary technology to harness the power of the immune system to combat cancer, announced the pricing of its initial public offering.

BrightEdge participated in the Series C funding round for Checkmate Pharmaceuticals.

BrightEdge participated in the $75 Million Series B Financing for Tmunity to Advance Next-Generation T-Cell Therapies

Freenome is a biotechnology company that has pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw

BrightEdge portfolio company, Castle Biosciences, has announced its intent to go public

The Wall Street Journal included BrightEdge in a look at the emergence of philanthropic venture funds to provide capital to medical startups. Bob Crutchfield, managing director of the BrightEdge fund, says such nonprofit funding vehicles nicely complement the role of the for-profit capital markets in accelerating the time it takes for promising healthcare innovations to get from patient trials to commercialization.

The quest to cure cancer might sound lofty, but plenty of researchers, scientists advocates and investors are chipping away it all the time. Now, the American Cancer Society is launching a new approach with BrightEdge, a philanthropic impact fund. It functions like a venture capital firm but with an altruistic goal: To find innovations in cancer treatment and invest in them so they can get to patients sooner. Bob Crutchfield, managing director of BrightEdge, joined The Show to talk about the venture and why the American Cancer Society wanted to go in this direction.

FOR IMMEDIATE RELEASE 2019-63 Washington D.C., April 30, 2019 — The Securities and Exchange Commission today announced that its Office of the Advocate for Small Business Capital Formation will host a roundtable on May 6 to hear from small businesses and their investors. The roundtable will celebrate the kickoff of National Small Business Week, which is May 5-11.

NEW YORK (GenomeWeb) — The American Cancer Society's (ACS) newly formed philanthropic fund BrightEdge has made its first investment, contributing $3 million to Castle Biosciences' $11.6 million convertible note financing last month, the organizations said on Thursday.

Convertible note investment in Castle Biosciences Inc., an innovator in skin-cancer diagnostics, is first deal for BrightEdge Impact Fund